JP2006516386A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516386A5
JP2006516386A5 JP2004540797A JP2004540797A JP2006516386A5 JP 2006516386 A5 JP2006516386 A5 JP 2006516386A5 JP 2004540797 A JP2004540797 A JP 2004540797A JP 2004540797 A JP2004540797 A JP 2004540797A JP 2006516386 A5 JP2006516386 A5 JP 2006516386A5
Authority
JP
Japan
Prior art keywords
hpv
polynucleotide sequence
pharmaceutical composition
polynucleotide
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004540797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516386A (ja
Filing date
Publication date
Priority claimed from GBGB0222953.2A external-priority patent/GB0222953D0/en
Application filed filed Critical
Publication of JP2006516386A publication Critical patent/JP2006516386A/ja
Publication of JP2006516386A5 publication Critical patent/JP2006516386A5/ja
Pending legal-status Critical Current

Links

JP2004540797A 2002-10-03 2003-10-01 ワクチン Pending JP2006516386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222953.2A GB0222953D0 (en) 2002-10-03 2002-10-03 Novel Compounds
PCT/EP2003/011158 WO2004031222A2 (en) 2002-10-03 2003-10-01 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus

Publications (2)

Publication Number Publication Date
JP2006516386A JP2006516386A (ja) 2006-07-06
JP2006516386A5 true JP2006516386A5 (https=) 2006-11-09

Family

ID=9945247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540797A Pending JP2006516386A (ja) 2002-10-03 2003-10-01 ワクチン

Country Status (21)

Country Link
US (2) US20060165713A1 (https=)
EP (1) EP1546191A2 (https=)
JP (1) JP2006516386A (https=)
KR (1) KR20050050115A (https=)
CN (1) CN100393878C (https=)
AR (1) AR041515A1 (https=)
AU (1) AU2003294672A1 (https=)
BR (1) BR0314986A (https=)
CA (1) CA2500093A1 (https=)
CO (1) CO5580837A2 (https=)
GB (1) GB0222953D0 (https=)
IS (1) IS7775A (https=)
MA (1) MA27474A1 (https=)
MX (1) MXPA05003558A (https=)
NO (1) NO20051561L (https=)
NZ (1) NZ539154A (https=)
PL (1) PL376534A1 (https=)
RU (1) RU2354701C2 (https=)
TW (1) TW200411055A (https=)
WO (1) WO2004031222A2 (https=)
ZA (1) ZA200503201B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
WO2008092854A2 (en) * 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
CN102985109B (zh) * 2010-06-25 2016-05-11 瓦西博迪公司 同型二聚体蛋白质构建体
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CA3023022A1 (en) * 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CN117203342A (zh) * 2020-11-25 2023-12-08 普雷西根公司 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
WO2002008435A1 (en) * 2000-07-21 2002-01-31 Glaxo Group Limited Codon-optimized papilloma virus sequences
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences

Similar Documents

Publication Publication Date Title
Yousefi et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy
Riemer et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers
Xu et al. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes
Lowy et al. Prophylactic human papillomavirus vaccines
Wang et al. Virus-like particles for the prevention of human papillomavirus-associated malignancies
Campo et al. Papillomavirus prophylactic vaccines: established successes, new approaches
JP2004504057A5 (https=)
Frazer Development and implementation of papillomavirus prophylactic vaccines
JP2019068852A5 (https=)
Gupta et al. HPV vaccines: Global perspectives
Stanley Progress in prophylactic and therapeutic vaccines for human papillomavirus infection
Tjalma et al. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer
JP2006501825A5 (https=)
JP2018518172A5 (https=)
Olczak et al. Progress in L2-based prophylactic vaccine development for protection against diverse human papillomavirus genotypes and associated diseases
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
US20090047302A1 (en) Chimaeric Human Papillomavirus 16 L1 Virus Like Particles and a Method for Preparing the Particles
Huber et al. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types
WO2009055491A3 (en) Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
Morand et al. Therapeutic vaccines for HPV-associated oropharyngeal and cervical cancer: the next de-intensification strategy?
Lowe et al. Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1
Jiang et al. Progress and prospects for L2-based human papillomavirus vaccines
JP2006516386A5 (https=)
Ahmed et al. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines
JP2019502404A5 (https=)